Treatment decision-making for leptomeningeal metastasis after TKI resistance in EGFR-mutant lung cancer: a comprehensive review on staging, resistance patterns, and multimodal interventions

Submitted by Anonymous on

Abstract Leptomeningeal metastasis (LM) represents a devastating complication in patients with EGFR-mutant non-small cell lung cancer (NSCLC) who develop resistance to tyrosine kinase inhibitors (TKIs). The management of LM after TKI resistance poses significant clinical challenges due to the heterogeneity...

The Epidermal Growth Factor Receptor (EGFR) as a means of neuro-immune cross-conversation

Submitted by Anonymous on

Abstract The nervous and the immune system coevolved, and the crosstalk between both is critical for the maintenance of tissue homeostasis and mental health. In recent years, several examples have been revealed that the immune system influences behaviour, emotions, pain...

EGFR-TKI monotherapy versus combination therapy as first-line treatment for EGFR-mutant NSCLC with brain metastases: a real-world comparison analysis

Submitted by Anonymous on

AbstractBackground Optimal first-line treatment for epidermal growth factor receptor (EGFR) mutant NSCLC with brain metastases (BMs) has not been fully defined. We aimed to compare different first-line tyrosine kinase inhibitor (TKI) combination therapies and monotherapy for these patients in a...

Paired ctDNA analysis reveals diverse resistance mechanisms to mobocertinib in EGFR exon 20 insertion NSCLC

Submitted by Anonymous on

BackgroundEpidermal growth factor receptor (EGFR) exon 20 insertion mutations in non-small cell lung cancer (NSCLC) represent a distinct molecular subset wit Abstract Background: Epidermal growth factor receptor (EGFR) exon 20 insertion mutations in non-small cell lung cancer (NSCLC) represent a...

Synthesis of new pyrazolo[3,4-d]pyrimidines as potential mutant EGFR/HER2 and Bcl2 inhibitors: anticancer evaluation, DFT, molecular docking and ADME studies

Submitted by Anonymous on

Abstract In this work, a novel 2-(6-methyl-4-oxo-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-3-yl)acetonitrile 4 was used as starting material to create a new series of pyrazolo[3,4-d]pyrimidines. DFT calculations and spectroscopic data (IR, 1H NMR, 13C NMR, and MS) were used to determine the structure of newly...

Subscribe to Newsfeed